CA2662126A1 - Anti cancer use of caffeic acid and its derivatives - Google Patents

Anti cancer use of caffeic acid and its derivatives Download PDF

Info

Publication number
CA2662126A1
CA2662126A1 CA002662126A CA2662126A CA2662126A1 CA 2662126 A1 CA2662126 A1 CA 2662126A1 CA 002662126 A CA002662126 A CA 002662126A CA 2662126 A CA2662126 A CA 2662126A CA 2662126 A1 CA2662126 A1 CA 2662126A1
Authority
CA
Canada
Prior art keywords
abl
bcr
dihydroxy
phenyl
propenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002662126A
Other languages
English (en)
French (fr)
Inventor
Kalpana Sanjay Joshi
Meenakshi Sivakumar
Valmik Sopan Aware
Vilas Sampatrao Wagh
Amit Deshpande
Ankush Gangaram Sarde
Somesh Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Enterprises Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2662126A1 publication Critical patent/CA2662126A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002662126A 2006-09-01 2007-08-20 Anti cancer use of caffeic acid and its derivatives Abandoned CA2662126A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84206006P 2006-09-01 2006-09-01
US60/842,060 2006-09-01
PCT/IB2007/053308 WO2008026125A2 (en) 2006-09-01 2007-08-20 Anti cancer use of caffeic acid and derivatives

Publications (1)

Publication Number Publication Date
CA2662126A1 true CA2662126A1 (en) 2008-03-06

Family

ID=39015871

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002662126A Abandoned CA2662126A1 (en) 2006-09-01 2007-08-20 Anti cancer use of caffeic acid and its derivatives

Country Status (12)

Country Link
US (1) US20100010002A1 (enExample)
EP (1) EP2061452B1 (enExample)
JP (1) JP2010502586A (enExample)
AT (1) ATE530176T1 (enExample)
AU (1) AU2007290960B2 (enExample)
CA (1) CA2662126A1 (enExample)
DK (1) DK2061452T3 (enExample)
ES (1) ES2376277T3 (enExample)
IL (1) IL197262A0 (enExample)
PT (1) PT2061452E (enExample)
TW (1) TW200812955A (enExample)
WO (1) WO2008026125A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052732A1 (en) * 2008-11-07 2010-05-14 Council Of Scientific & Industrial Research Cinnamido-pvrrolor[2,1-c][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
CN101456890B (zh) * 2008-12-17 2011-02-02 中南大学 白血病bcr/abl融合基因mRNA的特异性抑制剂
WO2010127440A1 (en) 2009-05-04 2010-11-11 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical uses thereof
KR20130010895A (ko) 2010-02-25 2013-01-29 피라말 엔터프라이지즈 리미티드 옥사디아졸 화합물, 그의 제조방법 및 용도
DK3443957T3 (da) 2010-10-27 2020-12-21 Liminal Biosciences Ltd Forbindelser og sammensætninger til behandling af cancer
US20140127316A1 (en) * 2011-05-20 2014-05-08 New York University Propolis and caffeic acid phenethyl ester and uses thereof
US20160194718A1 (en) * 2013-05-21 2016-07-07 Dana-Farber Cancer Institute, Inc. Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators
WO2017161093A1 (en) * 2016-03-17 2017-09-21 Musc Foundation For Research Development Caffeic acid derivatives and uses thereof
US20220370385A1 (en) * 2019-09-17 2022-11-24 Enzene Biosciences Ltd. Compositions for use in inhibiting src kinase and treating and preventing associated disorders
US11878971B2 (en) 2020-12-29 2024-01-23 Huscion Co., Ltd. Piperlongumine-based compound and immuno regulator comprising the same
EP4277896A4 (en) * 2021-01-14 2025-03-05 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University COMPOUNDS FOR STIMULATING AGAINST GASTRIC BIOFILM AND REDUCE INFLAMMATION, COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5008441A (en) * 1987-08-04 1991-04-16 The Trustees Of Columbia University In The City Of New York Caffeic acid esters and methods of producing and using same
EP1511475B1 (en) * 2002-05-31 2005-10-05 Council of Scientific and Industrial Research A herbal molecule as potential anti-leukemic drug
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
AU2003201062A1 (en) * 2002-07-08 2004-01-23 Council Of Scientific And Industrial Research A pharmaceutical composition useful for treating chronic myeloid leukemia
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20060045887A1 (en) 2004-08-25 2006-03-02 Gavish-Galilee Bio Applications Ltd. Mushroom extracts having anticancer activity

Also Published As

Publication number Publication date
US20100010002A1 (en) 2010-01-14
PT2061452E (pt) 2012-01-13
JP2010502586A (ja) 2010-01-28
AU2007290960B2 (en) 2013-04-18
DK2061452T3 (da) 2012-02-13
WO2008026125A3 (en) 2008-10-02
EP2061452B1 (en) 2011-10-26
TW200812955A (en) 2008-03-16
IL197262A0 (en) 2009-12-24
EP2061452A2 (en) 2009-05-27
AU2007290960A1 (en) 2008-03-06
WO2008026125A2 (en) 2008-03-06
ES2376277T3 (es) 2012-03-12
ATE530176T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
AU2007290960B2 (en) Anticancer use of caffeic acid and its derivatives
JP2010502586A5 (enExample)
JP6626437B2 (ja) ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ
EP3054954A1 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
JP2017019774A (ja) テロメラーゼ活性化化合物及びその使用方法
EP2433636A1 (en) Treatment of Malignant Diseases
AU2014318748B2 (en) Novel anthranilic amides and the use thereof
JP5289310B2 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
KR20230004595A (ko) 유방암 치료제
AU2016308704B2 (en) MDM2 inhibitors for treating uveal melanoma
US20150342909A1 (en) Therapeutic compounds and methods
US20170340688A1 (en) Titrated extracts of cynara scolymus and uses thereof
US20160213729A1 (en) Filipendula vulgaris extract and uses thereof
KR20180030075A (ko) 특정 비뇨기과 장애의 치료에 사용하기 위한 ｉｌ-8 억제제
TW201004614A (en) Use of diterpenes for treating prostate cancer
CN111905102A (zh) Ezh2抑制剂在治疗胶质瘤中的应用
US20230025625A1 (en) Radiation sensitivity enhancing comoposition containing aripiprazole as active ingredient
WO2024246717A1 (en) Mitochondria specific transcription inhibitors
CA3028461A1 (en) Combination therapies for treating cancer
US20170304223A1 (en) Method of treating prostate cancer using a pkc inhibitor
KR20240168426A (ko) 2-[(2-옥소-4-페닐-2h-크로멘-7-일)옥시]프로판아미도 유도체
HK40048076B (zh) 抗癌组合物
US20170224830A1 (en) PAK1-Activation Blocking Compounds, Preparation Thereof and Methods of Use
KR20200109545A (ko) 도파민 d2 수용체 저해제를 유효성분으로 함유하는 아리피프라졸의 방사선 민감화 효과 증진용 조성물
HK1202453A1 (en) Therapeutic composition for treating cancers

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140820